[
  {
    "ts": null,
    "headline": "Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data",
    "summary": "Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out why KYMR stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=6b8352564113406adc2502acb9290f74d48bfc7efa21c6e794b297ff26279252",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748876153,
      "headline": "Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data",
      "id": 134956005,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2208433943/image_2208433943.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out why KYMR stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=6b8352564113406adc2502acb9290f74d48bfc7efa21c6e794b297ff26279252"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response",
    "summary": "Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release. Pharmacokinetics (PK): KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorp",
    "url": "https://finnhub.io/api/news?id=c8a9f403ab4a68ff1bc1c820559a29b94ad16af73c32208b54fa6cb322b31881",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748874564,
      "headline": "Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response",
      "id": 134943563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release. Pharmacokinetics (PK): KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorp",
      "url": "https://finnhub.io/api/news?id=c8a9f403ab4a68ff1bc1c820559a29b94ad16af73c32208b54fa6cb322b31881"
    }
  },
  {
    "ts": null,
    "headline": "ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles",
    "summary": "Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.",
    "url": "https://finnhub.io/api/news?id=f871500bdae8d54eaec1f13cea9721c1b7daddc709cb4e605a6445b8fe3d7a28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748865390,
      "headline": "ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles",
      "id": 134936858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.",
      "url": "https://finnhub.io/api/news?id=f871500bdae8d54eaec1f13cea9721c1b7daddc709cb4e605a6445b8fe3d7a28"
    }
  },
  {
    "ts": null,
    "headline": "The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip",
    "summary": "CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing.  Regeneron's biggest growth driver is still performing well, and it is developing newer medicines.  For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN).",
    "url": "https://finnhub.io/api/news?id=dc20ef0039bd19410e4a2c3038b8f471fb9a352baba89e5a006bf60803f4dab9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748864700,
      "headline": "The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip",
      "id": 134937361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing.  Regeneron's biggest growth driver is still performing well, and it is developing newer medicines.  For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN).",
      "url": "https://finnhub.io/api/news?id=dc20ef0039bd19410e4a2c3038b8f471fb9a352baba89e5a006bf60803f4dab9"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
    "summary": "Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.",
    "url": "https://finnhub.io/api/news?id=9eb697d7edc61de1e4d974776ceb97fac1f874ac8315db8fa1ef2d29bb22b873",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748864640,
      "headline": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
      "id": 134937362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.",
      "url": "https://finnhub.io/api/news?id=9eb697d7edc61de1e4d974776ceb97fac1f874ac8315db8fa1ef2d29bb22b873"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist",
    "summary": "New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term health TARRYTOWN, N.Y., June 02, 2025 (GLOBE",
    "url": "https://finnhub.io/api/news?id=ad15b89224493941e66a02a95aaee10f1ae1376434bcbeeebc7053e5928297f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748862300,
      "headline": "Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist",
      "id": 134937364,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term health TARRYTOWN, N.Y., June 02, 2025 (GLOBE",
      "url": "https://finnhub.io/api/news?id=ad15b89224493941e66a02a95aaee10f1ae1376434bcbeeebc7053e5928297f6"
    }
  },
  {
    "ts": null,
    "headline": "Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass",
    "summary": "Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide alone – while also increasing loss of fat mass TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combination",
    "url": "https://finnhub.io/api/news?id=1da73041853ff4c447d01c9f4bd7f5289bdea3e4a532f89ca6692c3967e40025",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748862000,
      "headline": "Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass",
      "id": 134937365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide alone – while also increasing loss of fat mass TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combination",
      "url": "https://finnhub.io/api/news?id=1da73041853ff4c447d01c9f4bd7f5289bdea3e4a532f89ca6692c3967e40025"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi and Regeneron report results from two Phase III trials of COPD treatment",
    "summary": "The trials assessed the antibody's safety and efficacy in adult patients aged 40–85 years.",
    "url": "https://finnhub.io/api/news?id=e3132df40cb21f634c19057246cdb0195d8342168063bb65743b719b8e3ee30e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748860911,
      "headline": "Sanofi and Regeneron report results from two Phase III trials of COPD treatment",
      "id": 134938612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The trials assessed the antibody's safety and efficacy in adult patients aged 40–85 years.",
      "url": "https://finnhub.io/api/news?id=e3132df40cb21f634c19057246cdb0195d8342168063bb65743b719b8e3ee30e"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline",
    "summary": "The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.",
    "url": "https://finnhub.io/api/news?id=9fd32ed7e877743409d3899c2b0c7cc222840e1b8c43ce621a1774e406bf12b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748855460,
      "headline": "Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline",
      "id": 134936474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.",
      "url": "https://finnhub.io/api/news?id=9fd32ed7e877743409d3899c2b0c7cc222840e1b8c43ce621a1774e406bf12b5"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals - Interim Results From Ongoing Phase 2 Courage Trial",
    "summary": "Regeneron Pharmaceuticals Inc: * INTERIM RESULTS FROM ONGOING PHASE 2 COURAGE TRIAL CONFIRMPOTENTIAL TO IMPROVE THE QUALITY OF SEMAGLUTIDE -INDUCED WEIGHT LOSS...",
    "url": "https://finnhub.io/api/news?id=dee2af8fd334f4d664d903ff08e88d27ba1b5e2cb5ba8c7d047698914f626eb4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748853012,
      "headline": "Regeneron Pharmaceuticals - Interim Results From Ongoing Phase 2 Courage Trial",
      "id": 134936801,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals Inc: * INTERIM RESULTS FROM ONGOING PHASE 2 COURAGE TRIAL CONFIRMPOTENTIAL TO IMPROVE THE QUALITY OF SEMAGLUTIDE -INDUCED WEIGHT LOSS...",
      "url": "https://finnhub.io/api/news?id=dee2af8fd334f4d664d903ff08e88d27ba1b5e2cb5ba8c7d047698914f626eb4"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Expands Clinical-Stage Obesity Portfolio",
    "summary": "Regeneron Pharmaceuticals Inc: * REGENERON EXPANDS CLINICAL-STAGE OBESITY PORTFOLIO WITHSTRATEGIC IN-LICENSING OF NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST * REGENERON...",
    "url": "https://finnhub.io/api/news?id=e59edefe2bb53d1eac48750f03b4a6ab794993f82ebfe8164e64d2637543a0d7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748852233,
      "headline": "Regeneron Expands Clinical-Stage Obesity Portfolio",
      "id": 134936654,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals Inc: * REGENERON EXPANDS CLINICAL-STAGE OBESITY PORTFOLIO WITHSTRATEGIC IN-LICENSING OF NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST * REGENERON...",
      "url": "https://finnhub.io/api/news?id=e59edefe2bb53d1eac48750f03b4a6ab794993f82ebfe8164e64d2637543a0d7"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug",
    "summary": "By Adriano Marchese Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China. The...",
    "url": "https://finnhub.io/api/news?id=021351a436205ba09d7ec7f0100672965b61c1bc7cf40e719f09e822d85e2b1c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748850908,
      "headline": "Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug",
      "id": 134936342,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Adriano Marchese Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China. The...",
      "url": "https://finnhub.io/api/news?id=021351a436205ba09d7ec7f0100672965b61c1bc7cf40e719f09e822d85e2b1c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's weight-loss drug combo helps preserve muscle in study",
    "summary": "Regeneron Pharmaceuticalssaid on Monday a combination of its experimental drug and NovoNordisk's obesity drug Wegovy helped patients loseweight while preserving lean muscle mass in a mid-stage...",
    "url": "https://finnhub.io/api/news?id=0a77e7a4a07d6c1932111dc68d056624d816dff3a5d1cc60ce64d2d88d45ebd8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748849350,
      "headline": "Regeneron's weight-loss drug combo helps preserve muscle in study",
      "id": 134938194,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticalssaid on Monday a combination of its experimental drug and NovoNordisk's obesity drug Wegovy helped patients loseweight while preserving lean muscle mass in a mid-stage...",
      "url": "https://finnhub.io/api/news?id=0a77e7a4a07d6c1932111dc68d056624d816dff3a5d1cc60ce64d2d88d45ebd8"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron says its weight-loss drug helped preserve muscle mass in study",
    "summary": "Regeneron Pharmaceuticalssaid on Monday its experimental weight-loss drug combinationhelped preserve muscle mass in a mid-stage study. The drug candidate, trevogrumab, in combination...",
    "url": "https://finnhub.io/api/news?id=2f64a6911ab8a2e0ba84055bdb6de797b6b3aa2dd650afc68758a9ffc5f8e02b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748849350,
      "headline": "Regeneron says its weight-loss drug helped preserve muscle mass in study",
      "id": 134936169,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticalssaid on Monday its experimental weight-loss drug combinationhelped preserve muscle mass in a mid-stage study. The drug candidate, trevogrumab, in combination...",
      "url": "https://finnhub.io/api/news?id=2f64a6911ab8a2e0ba84055bdb6de797b6b3aa2dd650afc68758a9ffc5f8e02b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's weight-loss drug helps preserve muscle mass in study",
    "summary": "Regeneron Pharmaceuticalssaid on Monday its experimental weight-loss drug combinationhelped preserve muscle mass in a mid-stage study.(Reporting by Mariam Sunny in Bengaluru; Editing by...",
    "url": "https://finnhub.io/api/news?id=d696f1a7274175729c5fbaaaf2776991c2b1905b4a61f5c82d1f8c440df4f6b3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748848207,
      "headline": "Regeneron's weight-loss drug helps preserve muscle mass in study",
      "id": 134936064,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticalssaid on Monday its experimental weight-loss drug combinationhelped preserve muscle mass in a mid-stage study.(Reporting by Mariam Sunny in Bengaluru; Editing by...",
      "url": "https://finnhub.io/api/news?id=d696f1a7274175729c5fbaaaf2776991c2b1905b4a61f5c82d1f8c440df4f6b3"
    }
  }
]